Lilla Di Scala
Allschwil, BL, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
Evaluating Safety Rules in Ongoing Dose-Escalation Trials Using BOIN: A Comparative Analysis of Criteria and Their Impact on Dose-Level Safety Assessments.
Journal: Pharmaceutical statistics
Published: July 04, 2025
Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma.
Journal: The New England journal of medicine
Published: January 08, 2025
Correction: Jansa et al. Hospitalisation Is Prognostic of Survival in Chronic Thromboembolic Pulmonary Hypertension. J. Clin. Med. 2022, 11, 6189.
Journal: Journal of clinical medicine
Published: February 04, 2023
Hospitalisation Is Prognostic of Survival in Chronic Thromboembolic Pulmonary Hypertension.
Journal: Journal of clinical medicine
Published: September 02, 2022
Adjusting Overall Survival Estimates of Macitentan in Pulmonary Arterial Hypertension After Treatment Switching: Results from the SERAPHIN Study.
Journal: Advances in therapy
Published: June 01, 2022
Performance of DETECT Pulmonary Arterial Hypertension Algorithm According to the Hemodynamic Definition of Pulmonary Arterial Hypertension in the 2022 European Society of Cardiology and the European Respiratory Society Guidelines.
Journal: Arthritis & rheumatology (Hoboken, N.J.)
Published: April 26, 2022
Risk assessment in pulmonary arterial hypertension: Insights from the GRIPHON study.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
Published: May 03, 2019
Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study.
Journal: European journal of heart failure
Published: May 04, 2018
Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study.
Journal: American journal of cardiovascular drugs : drugs, devices, and other interventions
Published: January 08, 2018
An exploratory, open-label, randomized, multicenter study to investigate the pharmacodynamics of a glycoengineered antibody (imgatuzumab) and cetuximab in patients with operable head and neck squamous cell carcinoma.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: September 27, 2017
Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI2) Receptor Agonist in Pulmonary Arterial Hypertension (GRIPHON) study.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
Published: March 08, 2017
Last Updated: 09/26/2026